Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)
针对共同的非突变抗原和共同的突变BRAF新抗原的黑色素瘤疫苗的I/II期临床试验，采用激动性CD40抗体（CDX-1140）和TLR3激动剂（poly-ICLC）
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-013613
Ninmer, Emily K; Petroni, Gina R; Gastman, Brian R; Gaughan, Elizabeth M; Isaacs, James M; Haden, Kathleen; Kaur, Varinder; Wages, Nolan A; Chianese-Bullock, Kimberly A; Smith, Kelly T; Wright, Paul; Bryant, Jennifer; Dunlap-Brown, Marya; Engel, Jack A; Bekiranov, Stefan; Mauldin, Ileana S; Truong, Thach-Giao; Bullock, Timothy N J; Slingluff, Craig L Jr
